Search

Your search keyword '"Roeters-van Lennep, Jeanine E."' showing total 462 results
Start Over Author "Roeters-van Lennep, Jeanine E." Publication Year Range Last 10 years
462 results on '"Roeters-van Lennep, Jeanine E."'

4. Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy

Author

Beekman, Maarten J., Terra, Lara, Heemskerk-Gerritsen, Bernadette A.M., van der Aalst, Carlijn M., Roeters van Lennep, Jeanine E., van Beurden, Marc, van Doorn, Helena C., de Hullu, Joanne A., van Dorst, Eleonora B.L., Mom, Constantijne H., Mourits, Marian J.E., Slangen, Brigitte F.M., Bartels-Rutten, Annemarieke, Budde, Ricardo P.J., Snoeren, Miranda M., Leiner, Tim, de Jong, Pim A., Vliegenthart, Rozemarijn, Planken, R. Nils, Mihl, Casper, Vonder, Marleen, Oudkerk, Matthijs, Gaarenstroom, Katja N., Gratama, Jan Willem C., van Engelen, Klaartje, van der Kolk, Lizet E., Collée, J. Margriet, Wevers, Marijke R., Ausems, Margreet G.E.M., Berger, Lieke P.V., Gomez Garcia, Encarna B., van Asperen, Christi J., Hooning, Maartje J., de Koning, Harry J., Maas, Angela H.E.M., and van Leeuwen, Flora E.

Published
2024
Full Text
View/download PDF

13. Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women.

Author

van Oortmerssen, Julie A. E., Mulder, Janneke W. C. M., van der Bijl, Marte F., Mijnster, Ruben J. M., Kavousi, Maryam, and Roeters van Lennep, Jeanine E.

Abstract

Purpose of Review: The purpose of this review is to provide an overview of the current status of lipid-lowering therapy utilization and lipid goal attainment in women. We focus on lipid-lowering therapy in individuals with and without established atherosclerotic cardiovascular disease, as well as familial hypercholesterolemia. Additionally, this review aims to explore the underlying mechanisms driving these sex differences and to identify existing knowledge gaps in this area. Recent Findings: Despite the proven efficacy of lipid-lowering therapy in both sexes, real-world studies indicate that women with comparable risk profiles are less likely than men to receive these treatments. Furthermore, women who are prescribed statins typically receive lower-intensity regimens than men and are less likely to achieve guideline-recommended low-density lipoprotein cholesterol goals. Summary: Despite advancements in lipid-lowering therapies, women compared to men, are systematically undertreated. This difference is influenced by patient-related, physician-related, and societal factors. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

15. Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis

Author

Toloza, Freddy J K, Derakhshan, Arash, Männistö, Tuija, Bliddal, Sofie, Popova, Polina V, Carty, David M, Chen, Liangmiao, Taylor, Peter, Mosso, Lorena, Oken, Emily, Suvanto, Eila, Itoh, Sachiko, Kishi, Reiko, Bassols, Judit, Auvinen, Juha, López-Bermejo, Abel, Brown, Suzanne J, Boucai, Laura, Hisada, Aya, Yoshinaga, Jun, Shilova, Ekaterina, Grineva, Elena N, Vrijkotte, Tanja G M, Sunyer, Jordi, Jiménez-Zabala, Ana, Riaño-Galan, Isolina, Lopez-Espinosa, Maria-Jose, Prokop, Larry J, Singh Ospina, Naykky, Brito, Juan P, Rodriguez-Gutierrez, Rene, Alexander, Erik K, Chaker, Layal, Pearce, Elizabeth N, Peeters, Robin P, Feldt-Rasmussen, Ulla, Guxens, Mònica, Chatzi, Leda, Delles, Christian, Roeters van Lennep, Jeanine E, Pop, Victor J M, Lu, Xuemian, Walsh, John P, Nelson, Scott M, Korevaar, Tim I M, and Maraka, Spyridoula

Published
2022
Full Text
View/download PDF

16. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

Author

Tromp, Tycho R., Hartgers, Merel L., Hovingh, G. Kees, Vallejo-Vaz, Antonio J., Ray, Kausik K., Soran, Handrean, Freiberger, Tomas, Bertolini, Stefano A., Harada-Shiba, Mariko, Pang, Jing, Watts, Gerald F., Greber-Platzer, Susanne, Mäser, Martin, Stulnig, Thomas M., Ebenbichler, Christoph F., Bin Thani, Khalid, Cassiman, David, Descamps, Olivier S., Rymen, Daisy, Witters, Peter, Santos, Raul D., Brunham, Liam R., Francis, Gordon A., Genest, Jacques, Hegele, Robert A., Kennedy, Brooke A., Ruel, Isabelle, Sherman, Mark H., Jiang, Long, Wang, Luya, Reiner, Željko, Blaha, Vladimir, Ceska, Richard, Dvorakova, Jana, Dlouhy, Lubomir, Horak, Pavel, Soska, Vladimir, Tichy, Lukas, Urbanek, Robin, Vaverkova, Helena, Vrablik, Michal, Zemek, Stanislav, Zlatohlavek, Lukas, Emil, Sameh, Naguib, Tarek, Reda, Ashraf, Béliard, Sophie, Bruckert, Eric, Gallo, Antonio, Elisaf, Moses S., Kolovou, Genovefa, Cohen, Hofit, Durst, Ronen, Dann, Eldad J., Elis, Avishay, Hussein, Osama, Leitersdorf, Eran, Schurr, Daniel, Setia, Nitika, Verma, Ishwar C., Alareedh, Mohammed D., Al-Khnifsawi, Mutaz, Abdalsahib Al-Zamili, Ali F., Rhadi, Sabah H., Shaghee, Foaad K., Arca, Marcello, Averna, Maurizio, Bartuli, Andrea, Bucci, Marco, Buonuomo, Paola S., Calabrò, Paolo, Calandra, Sebastiano, Casula, Manuela, Catapano, Alberico L., Cefalù, Angelo B., Cicero, Arrigo F.G., D'Addato, Sergio, D'Erasmo, Laura, Di Costanzo, Alessia, Fasano, Tommaso, Gazzotti, Marta, Giammanco, Antonina, Iannuzzo, Gabriella, Ibba, Anastasia, Negri, Emanuele A., Pasta, Andrea, Pavanello, Chiara, Pisciotta, Livia, Rabacchi, Claudio, Ripoli, Carlo, Sampietro, Tiziana, Sbrana, Francesco, Sileo, Fulvio, Suppressa, Patrizia, Tarugi, Patrizia, Trenti, Chiara, Zenti, Maria G., Hori, Mika, Ayesh, Mahmoud H., Azar, Sami T., Bitar, Fadi F., Fahed, Akl C., Moubarak, Elie M., Nemer, Georges, Nawawi, Hapizah M., Madriz, Ramón, Mehta, Roopa, Cupido, Arjen J., Defesche, Joep C., Reijman, M. Doortje, Roeters-van Lennep, Jeanine E., Stroes, Erik S.G., Wiegman, Albert, Zuurbier, Linda, Al-Waili, Khalid, Sadiq, Fouzia, Chlebus, Krzysztof, Bourbon, Mafalda, Gaspar, Isabel M., Lalic, Katarina S., Ezhov, Marat V., Susekov, Andrey V., Groselj, Urh, Charng, Min-Ji, Khovidhunkit, Weerapan, Aktan, Melih, Altunkeser, Bulent B., Demircioglu, Sinan, Kose, Melis, Gokce, Cumali, Ilhan, Osman, Kayikcioglu, Meral, Kaynar, Leyla G., Kuku, Irfan, Kurtoglu, Erdal, Okutan, Harika, Ozcebe, Osman I., Pekkolay, Zafer, Sag, Saim, Salcioglu, Osman Z., Temizhan, Ahmet, Yenercag, Mustafa, Yilmaz, Mehmet, Yilmaz Yasar, Hamiyet, Mitchenko, Olena, Lyons, Alexander R.M., Stevens, Christophe A.T., Brothers, Julie A., Hudgins, Lisa C., Nguyen, Christina, Alieva, Rano, Shek, Aleksandr, Do, Doan-Loi, Kim, Ngoc-Thanh, Le, Hong-An, Le, Thanh-Tung, Nguyen, Mai-Ngoc T., Truong, Thanh-Huong, Blom, Dirk J., Raal, Frederick J., Cuchel, Marina, Tromp, Tycho R, Hartgers, Merel L, Hovingh, G Kees, Vallejo-Vaz, Antonio J, Ray, Kausik K, Bertolini, Stefano, Blom, Dirk J, and Raal, Frederick J

Published
2022
Full Text
View/download PDF

23. The Effect of Sargassum fusiforme and Fucus vesiculosus on Continuous Glucose Levels in Overweight Patients with Type 2 Diabetes Mellitus:A Feasibility Randomized, Double-Blind, Placebo-Controlled Trial

Author

Geurts, Karlijn A.M., Meijer, Sjoerd, Roeters van Lennep, Jeanine E., Wang, Xi, Özcan, Behiye, Voortman, Gardi, Liu, Hongbing, Castro Cabezas, Manuel, Berk, Kirsten A., Mulder, Monique T., Geurts, Karlijn A.M., Meijer, Sjoerd, Roeters van Lennep, Jeanine E., Wang, Xi, Özcan, Behiye, Voortman, Gardi, Liu, Hongbing, Castro Cabezas, Manuel, Berk, Kirsten A., and Mulder, Monique T.

Abstract

BACKGROUND: Brown seaweed is promising for the treatment of type 2 diabetes mellitus (T2DM). Its bioactive constituents can positively affect plasma glucose homeostasis in healthy humans. We investigated the effect of the brown seaweeds Sargassum (S.) fusiforme and Fucus (F.) vesiculosus in their natural form on glucose regulation in patients with T2DM. METHODS: We conducted a randomized, double-blind, placebo-controlled pilot trial. Thirty-six participants with T2DM received, on a daily basis, either 5 g of dried S. fusiforme, 5 g of dried F. vesiculosus, or 0.5 g of dried Porphyra (control) for 5 weeks, alongside regular treatment. The primary outcome was the between-group difference in the change in weekly average blood glucose levels (continuous glucose monitoring). The secondary outcomes were the changes in anthropometrics, plasma lipid levels, and dietary intake. The data were analyzed using a linear mixed-effects model. RESULTS: The change in weekly average glucose levels was 8.2 ± 2.1 to 9.0 ± 0.7 mmol/L (p = 0.2) in the S. fusiforme group (n = 12) and 10.1 ± 3.3 to 9.2 ± 0.7 mmol/L (p = 0.9) in the F. vesiculosus group (n = 10). The between-group difference was non-significant. Similarly, no between-group differences were observed for the changes in the secondary outcomes. DISCUSSION: A daily intake of 5 g of fresh, dried S. fusiforme or F. vesiculosus alongside regular treatment had no differential effect on weekly average blood glucose levels in T2DM.

Published
2024

24. Urinary incontinence more than 15 years after premenopausal risk-reducing salpingo-oophorectomy: a multicentre cross-sectional study

Author

MS Gynaecologische Oncologie, Cancer, Genetica Klinische Genetica, Terra, Lara, Heemskerk-Gerritsen, Bernadette A M, Beekman, Maarten J, Engelhardt, Ellen, Mourits, Marian J E, van Doorn, Helena C, de Hullu, Joanna A, Mom, Constantijne H, Slangen, Brigitte F M, Gaarenstroom, Katja N, van Beurden, Marc, Roeters Van Lennep, Jeanine E, van Dorst, Eleonora B L, van der Kolk, Lizet E, Collée, J Margriet, Wevers, Marijke R, Ausems, Margreet G E M, van Engelen, Klaartje, van de Beek, Irma, Berger, Lieke P V, van Asperen, Christi J, Gomez Garcia, Encarna B, Maas, Angela H E M, Hooning, Maartje J, Steensma, Anneke B, van Leeuwen, Flora E, MS Gynaecologische Oncologie, Cancer, Genetica Klinische Genetica, Terra, Lara, Heemskerk-Gerritsen, Bernadette A M, Beekman, Maarten J, Engelhardt, Ellen, Mourits, Marian J E, van Doorn, Helena C, de Hullu, Joanna A, Mom, Constantijne H, Slangen, Brigitte F M, Gaarenstroom, Katja N, van Beurden, Marc, Roeters Van Lennep, Jeanine E, van Dorst, Eleonora B L, van der Kolk, Lizet E, Collée, J Margriet, Wevers, Marijke R, Ausems, Margreet G E M, van Engelen, Klaartje, van de Beek, Irma, Berger, Lieke P V, van Asperen, Christi J, Gomez Garcia, Encarna B, Maas, Angela H E M, Hooning, Maartje J, Steensma, Anneke B, and van Leeuwen, Flora E

Published
2024

25. Lipid metabolism during pregnancy:Consequences for mother and child

Author

Mulder, Janneke W.C.M., Kusters, D. Meeike, Roeters Van Lennep, Jeanine E., Hutten, Barbara A., Mulder, Janneke W.C.M., Kusters, D. Meeike, Roeters Van Lennep, Jeanine E., and Hutten, Barbara A.

Abstract

Purpose of review:Accommodating fetal growth and development, women undergo multiple physiological changes during pregnancy. In recent years, several studies contributed to the accumulating evidence about the impact of gestational hyperlipidemia on cardiovascular risk for mother and child. This review aims to provide a comprehensive overview of the current research on lipid profile alterations during pregnancy and its associated (cardiovascular) outcomes for mother and child from a clinical perspective.Recent findings:In a normal pregnancy, total and LDL-cholesterol levels increase by approximately 30-50%, HDL-cholesterol by 20-40%, and triglycerides by 50-100%. In some women, for example, with familial hypercholesterolemia (FH), a more atherogenic lipid profile is observed. Dyslipidemia during pregnancy is found to be associated with adverse (cardiovascular) outcomes for the mother (e.g. preeclampsia, gestational diabetes, metabolic syndrome, unfavorable lipid profile) and for the child (e.g. preterm birth, large for gestational age, preatherosclerotic lesions, unfavorable lipid profile).Summary:The lipid profile of women during pregnancy provides a unique window of opportunity into the potential future cardiovascular risk for mother and child. Better knowledge about adverse outcomes and specific risk groups could lead to better risk assessment and earlier cardiovascular prevention. Future research should investigate implementation of gestational screening possibilities.

Published
2024

27. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy

Author

Terra, Lara, Beekman, Maarten J., Engelhardt, Ellen G., Heemskerk-Gerritsen, Bernadette A.M., van Beurden, Marc, Roeters van Lennep, Jeanine E., van Doorn, Helena C., de Hullu, Joanne A., Van Dorst, Eleonora B.L., Mom, Constantijne H., Slangen, Brigitte F.M., Gaarenstroom, Katja N., van der Kolk, Lizet E., Collée, J. Margriet, Wevers, Marijke R., Ausems, Margreet G.E.M., Van Engelen, Klaartje, van de Beek, Irma, Berger, Lieke P.V., van Asperen, Christi J., Gomez Garcia, Encarna B., Maas, Angela H.E.M., Hooning, Maartje J., Aaronson, Neil K., Mourits, Marian J.E., and van Leeuwen, Flora E.

Published
2023
Full Text
View/download PDF

29. The Effect of Sargassum fusiforme and Fucus vesiculosus on Continuous Glucose Levels in Overweight Patients with Type 2 Diabetes Mellitus: A Feasibility Randomized, Double-Blind, Placebo-Controlled Trial.

Author

Geurts, Karlijn A. M., Meijer, Sjoerd, Roeters van Lennep, Jeanine E., Wang, Xi, Özcan, Behiye, Voortman, Gardi, Liu, Hongbing, Castro Cabezas, Manuel, Berk, Kirsten A., and Mulder, Monique T.

Abstract

Background: Brown seaweed is promising for the treatment of type 2 diabetes mellitus (T2DM). Its bioactive constituents can positively affect plasma glucose homeostasis in healthy humans. We investigated the effect of the brown seaweeds Sargassum (S.) fusiforme and Fucus (F.) vesiculosus in their natural form on glucose regulation in patients with T2DM. Methods: We conducted a randomized, double-blind, placebo-controlled pilot trial. Thirty-six participants with T2DM received, on a daily basis, either 5 g of dried S. fusiforme, 5 g of dried F. vesiculosus, or 0.5 g of dried Porphyra (control) for 5 weeks, alongside regular treatment. The primary outcome was the between-group difference in the change in weekly average blood glucose levels (continuous glucose monitoring). The secondary outcomes were the changes in anthropometrics, plasma lipid levels, and dietary intake. The data were analyzed using a linear mixed-effects model. Results: The change in weekly average glucose levels was 8.2 ± 2.1 to 9.0 ± 0.7 mmol/L (p = 0.2) in the S. fusiforme group (n = 12) and 10.1 ± 3.3 to 9.2 ± 0.7 mmol/L (p = 0.9) in the F. vesiculosus group (n = 10). The between-group difference was non-significant. Similarly, no between-group differences were observed for the changes in the secondary outcomes. Discussion: A daily intake of 5 g of fresh, dried S. fusiforme or F. vesiculosus alongside regular treatment had no differential effect on weekly average blood glucose levels in T2DM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)

Author

Terra, Lara, Hooning, Maartje J, Heemskerk-Gerritsen, Bernadette A M, van Beurden, Marc, Roeters van Lennep, Jeanine E, van Doorn, Helena C, de Hullu, Joanne A, Mom, Constantijne, van Dorst, Eleonora B L, Mourits, Marian J E, Slangen, Brigitte F M, Gaarenstroom, Katja N, Zillikens, M Carola, Leiner, Tim, van der Kolk, Lizet, Collee, Margriet, Wevers, Marijke, Ausems, Margreet G E M, van Engelen, Klaartje, Berger, Lieke PV, van Asperen, Christi J, Gomez-Garcia, Encarna B, van de Beek, Irma, Rookus, Matti A, Hauptmann, Michael, Bleiker, Eveline M, Schagen, Sanne B, Aaronson, Neil K, Maas, Angela H E M, and van Leeuwen, Flora E

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundBRCA1/2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) at 35 to 45 years of age. RRSO substantially decreases ovarian cancer risk, but at the cost of immediate menopause. Knowledge about the potential adverse effects of premenopausal RRSO, such as increased risk of cardiovascular disease, osteoporosis, cognitive dysfunction, and reduced health-related quality of life (HRQoL), is limited. ObjectiveThe aim of this study is to assess the long-term health effects of premenopausal RRSO on cardiovascular disease, bone health, cognitive functioning, urological complaints, sexual functioning, and HRQoL in women with high familial risk of breast or ovarian cancer. MethodsWe will conduct a multicenter cross-sectional study with prospective follow-up, nested in a nationwide cohort of women at high familial risk of breast or ovarian cancer. A total of 500 women who have undergone RRSO before 45 years of age, with a follow-up period of at least 10 years, will be compared with 250 women (frequency matched on current age) who have not undergone RRSO or who have undergone RRSO at over 55 years of age. Participants will complete an online questionnaire on lifestyle, medical history, cardiovascular risk factors, osteoporosis, cognitive function, urological complaints, and HRQoL. A full cardiovascular assessment and assessment of bone mineral density will be performed. Blood samples will be obtained for marker analysis. Cognitive functioning will be assessed objectively with an online neuropsychological test battery. ResultsThis study was approved by the institutional review board in July 2018. In February 2019, we included our first participant. As of November 2020, we had enrolled 364 participants in our study. ConclusionsKnowledge from this study will contribute to counseling women with a high familial risk of breast/ovarian cancer about the long-term health effects of premenopausal RRSO. The results can also be used to offer health recommendations after RRSO. Trial RegistrationClinicalTrials.gov NCT03835793; https://clinicaltrials.gov/ct2/show/NCT03835793. International Registered Report Identifier (IRRID)DERR1-10.2196/24414

Published
2021
Full Text
View/download PDF

44. Early Onset of Coronary Artery Calcification in Women With Previous Preeclampsia

Author

Benschop, Laura, Brouwers, Laura, Zoet, Gerbrand A., Meun, Cindy, Boersma, Eric, Budde, Ricardo P.J., Fauser, Bart C.J.M., de Groot, Christianne M.J., van der Schouw, Yvonne T., Maas, Angela H.E.M., Velthuis, Birgitta K., Linstra, Katie M., Kavousi, Maryam, Duvekot, Johannes J., Franx, Arie, Steegers, Eric, van Rijn, Bas B., and Roeters van Lennep, Jeanine E.

Published
2020
Full Text
View/download PDF

47. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society

Author

Roeters van Lennep, Jeanine E, primary, Tokgözoğlu, Lale S, additional, Badimon, Lina, additional, Dumanski, Sandra M, additional, Gulati, Martha, additional, Hess, Connie N, additional, Holven, Kirsten B, additional, Kavousi, Maryam, additional, Kayıkçıoğlu, Meral, additional, Lutgens, Esther, additional, Michos, Erin D, additional, Prescott, Eva, additional, Stock, Jane K, additional, Tybjaerg-Hansen, Anne, additional, Wermer, Marieke J H, additional, and Benn, Marianne, additional

Published
2023
Full Text
View/download PDF

48. Urinary incontinence more than 15 years after premenopausal risk‐reducing salpingo‐oophorectomy: a multicentre cross‐sectional study

Author

Terra, Lara, primary, Heemskerk‐Gerritsen, Bernadette A. M., additional, Beekman, Maarten J., additional, Engelhardt, Ellen, additional, Mourits, Marian J. E., additional, van Doorn, Helena C., additional, de Hullu, Joanna A., additional, Mom, Constantijne H., additional, Slangen, Brigitte F. M., additional, Gaarenstroom, Katja N., additional, van Beurden, Marc, additional, Roeters Van Lennep, Jeanine E., additional, van Dorst, Eleonora B. L., additional, van der Kolk, Lizet E., additional, Collée, J. Margriet, additional, Wevers, Marijke R., additional, Ausems, Margreet G .E. M., additional, van Engelen, Klaartje, additional, van de Beek, Irma, additional, Berger, Lieke P. V., additional, van Asperen, Christi J., additional, Gomez Garcia, Encarna B., additional, Maas, Angela H. E. M., additional, Hooning, Maartje J., additional, Steensma, Anneke B., additional, and van Leeuwen, Flora E., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results